Brian Lee
Genentech
21 Papers
47 Citations
Brian Lee is an academic researcher from Genentech. The author has contributed to research in topics: Protein kinase B & Wound healing. The author has an hindex of 15, co-authored 20 publications. Previous affiliations of Brian Lee include New York University.
Chat about Author
Papers
Molecular pathogenesis of chronic wounds: The role of β-catenin and c-myc in the inhibition of epithelialization and wound healing
Olivera Stojadinovic,Harold Brem,Constantinos Vouthounis,Brian Lee,John T. Fallon,Michael R. Stallcup,Ankit Merchant,Robert D. Galiano,Marjana Tomic-Canic +8 more
TL;DR: It is concluded that activation of the beta-catenin/c-myc pathway(s) contributes to impaired healing by inhibiting keratinocyte migration and altering their differentiation.
Molecular markers in patients with chronic wounds to guide surgical debridement.
Harold Brem,Olivera Stojadinovic,Robert F. Diegelmann,Hyacinth Entero,Hyacinth Entero,Brian Lee,Irena Pastar,Michael S. Golinko,Harvey J. Rosenberg,Marjana Tomic-Canic +9 more
TL;DR: It is concluded that chronic ulcers contain distinct subpopulations of cells with different capacity to heal and that gene expression profiling can be utilized to identify them, thereby making surgical debridement more accurate and more efficacious.
367
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin,Deepak Sampath,Michelle Nannini,Brian Lee,Michael Degtyarev,Jason Oeh,Heidi Savage,Zhengyu Guan,Rebecca Hong,Robert Kassees,Leslie Lee,Tyler Risom,Stefan D. Gross,Bianca M. Liederer,Hartmut Koeppen,Nicholas J. Skelton,Jeffrey Wallin,Marcia Belvin,Elizabeth Punnoose,Lori Friedman,Kui Lin +20 more
TL;DR: GDC-0068 is a highly selective, orally bioavailable Akt kinase inhibitor that shows pharmacodynamic inhibition of Akt signaling and robust antitumor activity in human cancer cells in vitro and in vivo.
283
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
James F. Blake,Rui Xu,Josef R. Bencsik,Dengming Xiao,Nicholas C. Kallan,Stephen T. Schlachter,Ian S. Mitchell,Keith Lee Spencer,Banka Anna L,Eli M. Wallace,Susan L. Gloor,Matthew Martinson,Richard Woessner,Guy Vigers,Barbara J. Brandhuber,Jun Liang,Brian Safina,Jun Li,Birong Zhang,Christine Chabot,Steven Do,Leslie Lee,Jason Oeh,Deepak Sampath,Brian Lee,Kui Lin,Bianca M. Liederer,Nicholas J. Skelton +27 more
TL;DR: Biological studies with one 6,7-dihydro-5H-cyclopenta[d]pyrimidine compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated.
185
An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt
Kui Lin,Jie Lin,Wen-I Wu,Joshua Ballard,Brian Lee,Susan L. Gloor,Guy Vigers,Tony Morales,Lori Friedman,Nicholas J. Skelton,Barbara J. Brandhuber +10 more
TL;DR: A new model of kinase regulation is supported, wherein nucleotides modulate an on-off switch in Akt through conformational changes, which is disrupted by ATP-competitive inhibitors.
172